{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T01:38:49Z","timestamp":1788485929661,"version":"build-2803163510"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Hospital"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with generalized Myasthenia Gravis (gMG) may develop respiratory involvement, which can be life-threatening. In clinical practice, the Myasthenia Gravis Activities of Daily Living scale (MG-ADL) is often used to assess patient-reported respiratory impairment, as spirometry can be time-consuming and require specialized equipment and expertise. However, it is unclear whether the MG-ADL is a sufficient screening tool for identifying respiratory insufficiency.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this cross-sectional study with a longitudinal subgroup, patients completed the MG-ADL, the Myasthenia Gravis Composite scale (MGC), and the Quantitative Myasthenia Gravis score (QMG). As a part of the QMG, spirometry was conducted. All patients had one evaluation, and a subgroup of patients had an additional evaluation after 3\u00a0years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      One hundred patients were screened, and 70 were included and tested. Of these, 25 were retested 3\u00a0years later. Respiratory symptoms were reported by 30 (43%) of the 70 patients, though none reported severe symptoms. There was a poor correlation (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u2009\u2212\u00a00.24,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u2009.048) between the respiratory item of the MG-ADL and spirometry. Patients with respiratory insufficiency showed improvement over time, as did the MGC score.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings indicate limited agreement between patient-reported respiratory symptoms (MG-ADL) and spirometry measures, suggesting that spirometry remains essential for accurate assessment of respiratory function in gMG.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00415-026-13757-6","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T17:56:59Z","timestamp":1774375019000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Assessing respiratory status in myasthenia gravis: limited value of the MG-ADL as a standalone tool compared with spirometry in a Danish cohort"],"prefix":"10.1007","volume":"273","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4780-7739","authenticated-orcid":false,"given":"Linda Kahr","family":"Andersen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2358-788X","authenticated-orcid":false,"given":"Simone","family":"Birnbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3267-8038","authenticated-orcid":false,"given":"Malene","family":"Missel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine Gr\u00f8sfjeld","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6459-1505","authenticated-orcid":false,"given":"Cas","family":"Mohringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3693-8437","authenticated-orcid":false,"given":"Eva","family":"Deurell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0664-0709","authenticated-orcid":false,"given":"Nanna","family":"Witting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6144-8544","authenticated-orcid":false,"given":"John","family":"Vissing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"issue":"5","key":"13757_CR1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16229","volume":"31","author":"NE Gilhus","year":"2024","unstructured":"Gilhus NE, Andersen H, Andersen LK, Boldingh M, Laakso S, Leopoldsdottir MO et al (2024) Generalized myasthenia gravis with acetylcholine receptor antibodies: a guidance for treatment. Eur J Neurol 31(5):e16229. https:\/\/doi.org\/10.1111\/ene.16229","journal-title":"Eur J Neurol"},{"issue":"1","key":"13757_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/mus.24697","volume":"53","author":"JS Hansen","year":"2016","unstructured":"Hansen JS, Danielsen DH, Somnier FE, Fr\u00f8slev T, Jakobsen J, Johnsen SP et al (2016) Mortality in myasthenia gravis: a nationwide population-based follow-up study in Denmark. Muscle Nerve 53(1):73\u201377. https:\/\/doi.org\/10.1002\/mus.24697","journal-title":"Muscle Nerve"},{"key":"13757_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2025.123493","volume":"473","author":"LK Andersen","year":"2025","unstructured":"Andersen LK, Petersen KG, Deurell EM, Lagoni A, Kaalund AB, Flensted IF et al (2025) EQ-5D-5L is a relevant tool for detecting patients with myasthenia gravis needing medical treatment. J Neurol Sci 473:123493. https:\/\/doi.org\/10.1016\/j.jns.2025.123493","journal-title":"J Neurol Sci"},{"issue":"7","key":"13757_CR4","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.1007\/s00415-023-11733-y","volume":"270","author":"NE Gilhus","year":"2023","unstructured":"Gilhus NE (2023) Myasthenia gravis, respiratory function, and respiratory tract disease. J Neurol 270(7):3329\u20133340. https:\/\/doi.org\/10.1007\/s00415-023-11733-y","journal-title":"J Neurol"},{"key":"13757_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nmd.2024.05.005","volume":"40","author":"M Alcantara","year":"2024","unstructured":"Alcantara M, Barnett-Tapia C, Bril V, Mannan S, Shabanpour J, Riaz S et al (2024) Office-based respiratory assessment in patients with generalized myasthenia gravis. Neuromuscul Disord 40:1\u20136. https:\/\/doi.org\/10.1016\/j.nmd.2024.05.005","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"13757_CR6","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.nmd.2016.11.015","volume":"27","author":"EF Oliveira","year":"2017","unstructured":"Oliveira EF, Nacif SR, Urbano JJ, Silva AS, Oliveira CS, Perez EA et al (2017) Sleep, lung function, and quality of life in patients with myasthenia gravis: a cross-sectional study. Neuromuscul Disord NMD 27(2):120\u2013127. https:\/\/doi.org\/10.1016\/j.nmd.2016.11.015","journal-title":"Neuromuscul Disord NMD"},{"issue":"6","key":"13757_CR7","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.nrleng.2020.09.006","volume":"38","author":"F Aguirre","year":"2023","unstructured":"Aguirre F, Fern\u00e1ndez RN, Arrejor\u00eda RM, Manin A, Cores VE, Sivori M et al (2023) Peak expiratory flow and the single-breath count test as markers of respiratory function in patients with myasthenia gravis. Neurol Engl Ed 38(6):405\u2013411. https:\/\/doi.org\/10.1016\/j.nrleng.2020.09.006","journal-title":"Neurol Engl Ed"},{"issue":"7","key":"13757_CR8","doi-asserted-by":"publisher","first-page":"3682","DOI":"10.1007\/s00415-022-10990-7","volume":"269","author":"S Teeselink","year":"2022","unstructured":"Teeselink S, Vincenten SCC, Voermans NC, Groothuis JT, Doorduin J, Wijkstra PJ et al (2022) Long-term follow-up of respiratory function in facioscapulohumeral muscular dystrophy. J Neurol 269(7):3682\u20133689. https:\/\/doi.org\/10.1007\/s00415-022-10990-7","journal-title":"J Neurol"},{"issue":"6","key":"13757_CR9","doi-asserted-by":"publisher","first-page":"3086","DOI":"10.1007\/s00415-021-10902-1","volume":"269","author":"LK Andersen","year":"2022","unstructured":"Andersen LK, Jakobsson AS, Revsbech KL, Vissing J (2022) Causes of symptom dissatisfaction in patients with generalized myasthenia gravis. J Neurol 269(6):3086\u20133093. https:\/\/doi.org\/10.1007\/s00415-021-10902-1","journal-title":"J Neurol"},{"issue":"12","key":"13757_CR10","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJM198703193161205","volume":"316","author":"RS Tindall","year":"1987","unstructured":"Tindall RS, Rollins JA, Phillips JT, Greenlee RG, Wells L, Belendiuk G (1987) Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med 316(12):719\u2013724. https:\/\/doi.org\/10.1056\/NEJM198703193161205","journal-title":"N Engl J Med"},{"issue":"8","key":"13757_CR11","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1164\/rccm.201908-1590ST","volume":"200","author":"BL Graham","year":"2019","unstructured":"Graham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper BG, Hall GL et al (2019) Standardization of spirometry 2019 update. An official American Thoracic Society and European Respiratory Society technical statement. Am J Respir Crit Care Med 200(8):e70-88. https:\/\/doi.org\/10.1164\/rccm.201908-1590ST","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"13757_CR12","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1183\/09031936.00080312","volume":"40","author":"PH Quanjer","year":"2012","unstructured":"Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH et al (2012) Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J 40(6):1324\u20131343. https:\/\/doi.org\/10.1183\/09031936.00080312","journal-title":"Eur Respir J"},{"issue":"7","key":"13757_CR13","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","volume":"52","author":"GI Wolfe","year":"1999","unstructured":"Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ (1999) Myasthenia gravis activities of daily living profile. Neurology 52(7):1487\u20131489","journal-title":"Neurology"},{"issue":"7","key":"13757_CR14","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1007\/s00415-020-09770-y","volume":"267","author":"J Vissing","year":"2020","unstructured":"Vissing J, Jacob S, Fujita KP, O\u2019Brien F, Howard JF, REGAIN study group (2020) \u201cMinimal symptom expression\u201d in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab. J Neurol 267(7):1991\u20132001. https:\/\/doi.org\/10.1007\/s00415-020-09770-y","journal-title":"J Neurol"},{"issue":"6","key":"13757_CR15","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1002\/mus.21185","volume":"38","author":"TM Burns","year":"2008","unstructured":"Burns TM, Conaway MR, Cutter GR, Sanders DB, Muscle Study Group (2008) Construction of an efficient evaluative instrument for myasthenia gravis: the MG composite. Muscle Nerve 38(6):1553\u20131562. https:\/\/doi.org\/10.1002\/mus.21185","journal-title":"Muscle Nerve"},{"issue":"1","key":"13757_CR16","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/mus.24929","volume":"53","author":"B Elsheikh","year":"2016","unstructured":"Elsheikh B, Arnold WD, Gharibshahi S, Reynolds J, Freimer M, Kissel JT (2016) Correlation of single-breath count test and neck flexor muscle strength with spirometry in myasthenia gravis. Muscle Nerve 53(1):134\u2013136. https:\/\/doi.org\/10.1002\/mus.24929","journal-title":"Muscle Nerve"},{"key":"13757_CR17","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1749-6632.2012.06812.x","volume":"1274","author":"TM Burns","year":"2012","unstructured":"Burns TM (2012) The MG composite: an outcome measure for myasthenia gravis for use in clinical trials and everyday practice. Ann N Y Acad Sci 1274:99\u2013106. https:\/\/doi.org\/10.1111\/j.1749-6632.2012.06812.x","journal-title":"Ann N Y Acad Sci"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13757-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-13757-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13757-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T01:48:31Z","timestamp":1776649711000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-026-13757-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["13757"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-13757-6","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"19 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JV received an unrestricted grant from UCB Pharmaceutical to cover salary and patient transport. However, the company did not influence the study design or the manuscript. The remaining authors report no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"231"}}